• Potential Gene Therapy for Familial ALS Named Orphan Drug by EMA
  • #ERDC2018 – New EU Law to Protect Patient Data Could Affect Rare Disease Registries
  • Clinigen, Mitsubishi Tanabe Announce Early Access Program in Europe for ALS Therapy Radicava
  • Voyager Shares Promising Pre-clinical Data About ALS Therapy Candidate VY-SOD101
  • How I Cruise Through the Slow Lane of ALS
  • New Mouse Model Reveals Process Involved in Neuroinflammation in ALS, Other Disorders
  • Protein That Helps to Regulate Innate Immune System Seen to Slow ALS Progression in Early Study in Mice
  • #ECRD2018 – EU Must Do More for Rare Disease Patients, Eurordis Leaders Say
  • ‘Rare Impact Awards’ Dinner Marks Orphan Drug Act and NORD at 35
  • Specially Engineered Neural Cells Delay Disease and Extend Life in ALS Animal Model
  • MDA Grants Include Research Projects for ALS and Other Diseases
  • Let’s Raise Awareness About the Many Looks of ALS